NAD(P)H oxidase isoforms as therapeutic targets for diabetic complications

References

• Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001;14(5 Pt 1):475-86
   PubMedGoogle Scholar
• Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 2007;9(6):767-80
   PubMed Web of Science ®Google Scholar
• Bryden KS, Dunger DB, Mayou RA, et al. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care 2003;26(4):1052-7
   PubMed Web of Science ®Google Scholar
• Diabetes-Australia. Diabetes in Australia; Diabetes Globally. 2011
   Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year. 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53
   PubMed Web of Science ®Google Scholar
• Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003;108(12):1527-32
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376(9735):124-36
   PubMed Web of Science ®Google Scholar
• Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diab Rep 2011;11(4):253-64
   PubMed Web of Science ®Google Scholar
• Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol 2011;170:36-47
   PubMed Web of Science ®Google Scholar
• Valk EJ, Bruijn JA, Bajema IM. Diabetic nephropathy in humans: pathologic diversity. Curr Opin Nephrol Hypertens 2011;20(3):285-9
   PubMedGoogle Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30(1):162-72
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010;6(6):319-30
   PubMed Web of Science ®Google Scholar
• Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 2005;68(Suppl 2):S3-14
   PubMedGoogle Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39
   PubMed Web of Science ®Google Scholar
• Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013;127(18):1888-902
   PubMed Web of Science ®Google Scholar
• Sedeek M, Montezano AC, Hebert RL, et al. Oxidative stress, Nox isoforms and complications of diabetes – potential targets for novel therapies. J Cardiovasc Transl Res 2012;5(4):509-18
   PubMedGoogle Scholar
• Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011;7(3):176-84
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107(9):1058-70
   PubMed Web of Science ®Google Scholar
• Gradinaru D, Borsa C, Ionescu C, Margina D. Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics 2013;92:313-22
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Mahadev K, Wu X, et al. Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid Redox Signal 2005;7(7-8):1021-31
   PubMed Web of Science ®Google Scholar
• Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 2010;15(2):50-63
   PubMed Web of Science ®Google Scholar
• Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87(1):245-313
   PubMed Web of Science ®Google Scholar
• Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 2006;8(9-10):1597-607
   PubMed Web of Science ®Google Scholar
• Lassègue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 2010;30(4):653-61
   PubMed Web of Science ®Google Scholar
• Gorin Y, Block K, Hernandez J, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005;280(47):39616-26
   PubMedGoogle Scholar
• Gorin Y, Block K. Nox as a target for diabetic complications. Clin Sci 2013;125(8):361-82
   Google Scholar
• Guzik TJ, Sadowski J, Guzik B, et al. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 2006;26(2):333-9
   PubMed Web of Science ®Google Scholar
• Serrander L, Cartier L, Bedard K, et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 2007;406(1):105-14
   PubMedGoogle Scholar
• Schmidt HH, Wingler K, Kleinschnitz C, Dusting G. NOX4 is a janus-faced reactive oxygen species generating NADPH oxidase. Circ Res 2012;111(1):e15-16
   Google Scholar
• de Dios ST, Sobey CG, Drummond GR. Oxidative stress and endothelial dysfunction. In: Endothelial dysfunction inflammation. Springer Basel: Basel, Switzerland; 2010. p. 37
   Google Scholar
• Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87(4):1620-4
   PubMed Web of Science ®Google Scholar
• Judkins CP, Diep H, Broughton BRS, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE -/- mice. Am J Physiol Heart Circ Physiol 2010;298(1):H24-32
   Google Scholar
• Kagota S, Kubota Y, Nejime N, et al. Impaired effect of salt loading on nitric oxide-mediated relaxation in aortas from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2007;34(1-2):48-54
   PubMedGoogle Scholar
• Maneen MJ, Cipolla MJ. Peroxynitrite diminishes myogenic tone in cerebral arteries: role of nitrotyrosine and F-actin. Am J Physiol Heart Circ Physiol 2007;292(2):H1042-50
   Google Scholar
• Qian J, Chen F, Kovalenkov Y, et al. Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation. Free Radic Biol & Med 2012;52(9):1806-19
   PubMedGoogle Scholar
• Santos CX, Nabeebaccus AA, Shah AM, et al. Endoplasmic reticulum stress and nox-mediated reactive oxygen species signaling in the peripheral vasculature: potential role in hypertension. Antioxid Redox Signal 2014;20(1):121-34
   PubMed Web of Science ®Google Scholar
• Lee DY, Wauquier F, Eid AA, et al. Nox4 NADPH oxidase mediates peroxynitrite-dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: role of mitochondrial reactive oxygen species. J Biol Chem 2013;288(40):28668-86
   PubMed Web of Science ®Google Scholar
• Kroller-Schon S, Steven S, Kossmann S, et al. Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal 2014;20(2):247-66
   PubMed Web of Science ®Google Scholar
• Shen GX. Mitochondrial dysfunction, oxidative stress and diabetic cardiovascular disorders. Cardiovasc Hematol Disord Drug Targets 2012;12(2):106-12
   PubMedGoogle Scholar
• Chen K, Kirber MT, Xiao H, et al. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol 2008;181(7):1129-39
   Web of Science ®Google Scholar
• Pedruzzi E, Guichard C, Ollivier V, et al. NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol Cell Biol 2004;24(24):10703-17
   PubMed Web of Science ®Google Scholar
• Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009;11(10):2409-27
   PubMed Web of Science ®Google Scholar
• Wu RF, Ma Z, Liu Z, Terada LS. Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local Ras activation. Mol Cell Biol 2010;30(14):3553-68
   PubMed Web of Science ®Google Scholar
• Janiszewski M, Lopes LR, Carmo AO, et al. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J Biol Chem 2005;280(49):40813-19
   PubMedGoogle Scholar
• Zhang M, Brewer AC, Schroder K, et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 2010;107(42):18121-6
   PubMed Web of Science ®Google Scholar
• Frazziano G, Al Ghouleh I, Baust J, et al. Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension; indications for a seminal role for mitochondrial Nox4. Am J Physiol Heart Circ Physiol 2014;306(2):H197-205
   Google Scholar
• Koziel R, Pircher H, Kratochwil M, et al. Mitochondrial respiratory chain complex I is inactivated by NADPH oxidase Nox4. Biochem J 2013;452(2):231-9
   PubMedGoogle Scholar
• Graham KA, Kulawiec M, Owens KM, et al. NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol Ther 2010;10(3):223-31
   PubMed Web of Science ®Google Scholar
• Babior BM. The leukocyte NADPH oxidase. Isr Med Assoc J 2002;4(11):1023-4
   PubMed Web of Science ®Google Scholar
• Touyz RM, Yao G, Schiffrin EL. Role of the actin cytoskeleton in angiotensin II signaling in human vascular smooth muscle cells. Can J Physiol Pharmacol 2005;83(1):91-7
   PubMedGoogle Scholar
• Wendt MC, Daiber A, Kleschyov AL, et al. Differential effects of diabetes on the expression of the gp91 phox homologues nox1 and nox4. Free Radic Biol Med 2005;39(3):381-91
   PubMedGoogle Scholar
• Yogi A, Mercure C, Touyz J, et al. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 2008;51(2 Pt 2):500-6
   PubMedGoogle Scholar
• Hilenski LL, Clempus RE, Quinn MT, et al. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004;24(4):677-83
   PubMedGoogle Scholar
• Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999;401(6748):79-82
   PubMed Web of Science ®Google Scholar
• Ellmark SHM, Dusting GJ, Ng Tang Fui M, et al. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res 2005;65(2):495-504
   PubMedGoogle Scholar
• Lee JG, Lim EJ, Park DW, et al. A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal 2008;20(12):2266-75
   PubMedGoogle Scholar
• Guzik TJ, Chen W, Gongora MC, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 2008;52(22):1803-9
   PubMedGoogle Scholar
• Montezano AC, Burger D, Paravicini TM, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res 2010;106(8):1363-73
   PubMedGoogle Scholar
• Pi J, Bai Y, Zhang Q, et al. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 2007;56(7):1783-91
   PubMed Web of Science ®Google Scholar
• Morgan D, Rebelato E, Abdulkader F, et al. Association of NAD(P)H oxidase with glucose-induced insulin secretion by pancreatic beta-cells. Endocrinology 2009;150(5):2197-201
   PubMed Web of Science ®Google Scholar
• Newsholme P, Morgan D, Rebelato E, et al. Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic beta cell. Diabetologia 2009;52(12):2489-98
   PubMed Web of Science ®Google Scholar
• Taylor-Fishwick DA. NOX, NOX Who is there? the contribution of NADPH oxidase one to beta cell dysfunction. Front Endocrinol 2013;4:40
   PubMedGoogle Scholar
• Morgan D, Oliveira-Emilio HR, Keane D, et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 2007;50(2):359-69
   PubMed Web of Science ®Google Scholar
• Wind S, Beuerlein K, Eucker T, et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 2010;161(4):885-98
   PubMed Web of Science ®Google Scholar
• Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci USA 2009;106(34):14385-90
   PubMedGoogle Scholar
• Dorman JS, Laporte RE, Kuller LH, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984;33(3):271-6
   PubMedGoogle Scholar
• Lago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab 2007;3(10):667
   PubMedGoogle Scholar
• Bengtsson SHM, Gulluyan LM, Dusting GJ, Drummond GR. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 2003;30(11):849-54
   PubMed Web of Science ®Google Scholar
• Chen F, Haigh S, Barman S, Fulton DJ. From form to function: the role of Nox4 in the cardiovascular system. Front Physiol 2012;3:412
   PubMedGoogle Scholar
• Sorescu D, Weiss D, Lassègue B, et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 2002;105(12):1429-35
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002;105(14):1656-62
   PubMed Web of Science ®Google Scholar
• Zalba G, San Jose G, Moreno MU, et al. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 2005;7(9-10):1327-36
   PubMedGoogle Scholar
• Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001;19(7):1245-54
   PubMed Web of Science ®Google Scholar
• Touyz RM, Yao G, Quinn MT, et al. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 2005;25(3):512-18
   PubMedGoogle Scholar
• Akasaki T, Ohya Y, Kuroda J, et al. Increased expression of gp91phox homologues of NAD(P)H oxidase in the aortic media during chronic hypertension: involvement of the renin-angiotensin system. Hypertens Res 2006;29(10):813-20
   PubMedGoogle Scholar
• Calkin AC, Giunti S, Sheehy KJ, et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008;51(9):1731-40
   PubMedGoogle Scholar
• Lassègue B, Sorescu D, Szöcs K, et al. Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001;88(9):888-94
   PubMed Web of Science ®Google Scholar
• Tong X, Schröder K. NADPH oxidases are responsible for the failure of nitric oxide to inhibit migration of smooth muscle cells exposed to high glucose. Free Radic Biol Med 2009;47(11):1578-83
   PubMedGoogle Scholar
• Watson AMD, Li J, Schumacher C, et al. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein e knockout mice. Diabetologia 2010;53(1):192-203
   PubMedGoogle Scholar
• Holterman CE, Thibodeau JF, Towaij C, et al. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Sheehan AL, Carrell S, Johnson B, et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 2011;216(2):321-6
   PubMed Web of Science ®Google Scholar
• Touyz RM, Montezano AC. Vascular Nox4: a multifarious NADPH oxidase. Circ Res 2012;110(9):1159-61
   PubMed Web of Science ®Google Scholar
• Schroder K, Zhang M, Benkhoff S, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 2012;110(9):1217-25
   PubMedGoogle Scholar
• Ray R, Murdoch CE, Wang M, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 2011;31(6):1368-76
   PubMedGoogle Scholar
• Maalouf RM, Eid AA, Gorin YC, et al. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am J Physiol Cell Physiol 2012;302(3):C597-604
   Google Scholar
• Gavazzi G, Banfi B, Deffert C, et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 2006;580(2):497-504
   PubMedGoogle Scholar
• Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005;112(17):2677-85
   PubMedGoogle Scholar
• Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005;112(17):2668-76
   PubMed Web of Science ®Google Scholar
• Wingler K, Wunsch S, Kreutz R, et al. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001;31(11):1456-64
   PubMedGoogle Scholar
• Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 2013;19(10):1110-20
   PubMedGoogle Scholar
• Oak JH, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007;56(1):118-26
   PubMedGoogle Scholar
• Takaya T, Kawashima S, Shinohara M, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006;186(2):402-10
   PubMedGoogle Scholar
• Perrins CJ, Bobryshev YV. Current advances in understanding of immunopathology of atherosclerosis. Virchows Arch 2011;458(2):117-23
   PubMedGoogle Scholar
• Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008;24(1):14-26
   PubMed Web of Science ®Google Scholar
• Wong WT, Tian XY, Xu A, et al. Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal 2010;13(6):757-68
   PubMedGoogle Scholar
• Honjo T, Yamaoka-Tojo M, Inoue N. Pleiotropic effects of ARB in vascular metabolism – focusing on atherosclerosis-based cardiovascular disease. Curr Vasc Pharmacol 2011;9(2):145-52
   PubMedGoogle Scholar
• Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004;27(Suppl 1):S79-83
   PubMedGoogle Scholar
• Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352(9123):213-19
   PubMed Web of Science ®Google Scholar
• Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288(20):2579-88
   PubMed Web of Science ®Google Scholar
• Zou AP, Li N, Cowley AW Jr. Production and actions of superoxide in the renal medulla. Hypertension 2001;37(2 Pt 2):547-53
   PubMedGoogle Scholar
• Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55(1):225-33
   PubMed Web of Science ®Google Scholar
• Eid AA, Ford BM, Block K, et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem 2010;285(48):37503-12
   PubMed Web of Science ®Google Scholar
• Eid AA, Gorin Y, Fagg BM, et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009;58(5):1201-11
   PubMed Web of Science ®Google Scholar
• Chabrashvili T, Tojo A, Onozato ML, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002;39(2 I):269-74
   PubMedGoogle Scholar
• You YH, Okada S, Ly S, et al. Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol 2013;304(7):F840-8
   Google Scholar
• Gorin Y, Block K. Nox4 and diabetic nephropathy: With a friend like this, who needs enemies? Free Radic Biol Med 2013;61C:130-42
   Google Scholar
• Babelova A, Avaniadi D, Jung O, et al. Role of Nox4 in murine models of kidney disease. Free Radic Biol Med 2012;53(4):842-53
   PubMedGoogle Scholar
• Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2010;299(6):F1348-58
   PubMed Web of Science ®Google Scholar
• Etoh T, Inoguchi T, Kakimoto M, et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 2003;46(10):1428-37
   PubMed Web of Science ®Google Scholar
• Gorin Y, Ricono JM, Kim NH, et al. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 2003;285(2):F219-29
   Google Scholar
• New DD, Block K, Bhandhari B, et al. IGF-I increases the expression of fibronectin by Nox4-dependent Akt phosphorylation in renal tubular epithelial cells. Am J Physiol Cell Physiol 2012;302(1):C122-30
   Google Scholar
• Jha JC, Gray SP, Barit D, et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provide renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 2014; In press
   PubMedGoogle Scholar
• Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003;285(1):R117-24
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Yoshizumi M, Hitomi H, et al. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 2004;15(2):306-15
   PubMedGoogle Scholar
• Asaba K, Tojo A, Onozato ML, et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005;67(5):1890-8
   PubMed Web of Science ®Google Scholar
• Shi XY, Hou FF, Niu HX, et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008;149(4):1829-39
   PubMed Web of Science ®Google Scholar
• Xiang FL, Lu X, Strutt B, et al. NOX2 deficiency protects against streptozotocin-induced beta-cell destruction and development of diabetes in mice. Diabetes 2010;59(10):2603-11
   PubMed Web of Science ®Google Scholar
• Ola MS, Nawaz MI, Siddiquei MM, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J Diabetes Complications 2012;26(1):56-64
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102(1):7-16
   PubMed Web of Science ®Google Scholar
• Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 2003;35(11):1491-9
   PubMed Web of Science ®Google Scholar
• Frey T, Antonetti DA. Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid Redox Signal 2011;15(5):1271-84
   PubMedGoogle Scholar
• Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 2000;28(1):91-101
   PubMedGoogle Scholar
• Chen P, Guo AM, Edwards PA, et al. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 2007;293(4):R1619-29
   PubMed Web of Science ®Google Scholar
• Yokota H, Narayanan SP, Zhang W, et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Invest Ophthalmol Vis Sci 2011;52(11):8123-31
   PubMedGoogle Scholar
• Li J, Wang JJ, Yu Q, et al. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes 2010;59(6):1528-38
   PubMed Web of Science ®Google Scholar
• Li L, Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006;55(11):1516-23
   PubMed Web of Science ®Google Scholar
• Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009;104(1):124-33
   PubMed Web of Science ®Google Scholar
• Al-Shabrawey M, Rojas M, Sanders T, et al. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 2008;49(7):3239-44
   PubMedGoogle Scholar
• Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis 2007;13:840-53
   PubMed Web of Science ®Google Scholar
• Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49(7):3231-8
   PubMed Web of Science ®Google Scholar
• Yamagishi S-i, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue rage expression in diabetes. Arterioscler Thromb Vasc Biol 2007;27(6):e32
   Google Scholar
• Wilkinson-Berka JL, Deliyanti D, Rana I, et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Aldieri E, Riganti C, Polimeni M, et al. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 2008;9(8):686-96
   PubMed Web of Science ®Google Scholar
• Gatley SJ, Sherratt HSA. The effects of diphenyleneiodonium on mitochondrial reactions. Relation of binding of diphenylene[125I]iodonium to mitochondria to the extent of inhibition of oxygen uptake. Biochem J 1976;158(2):307-15
   PubMedGoogle Scholar
• Ragan CI, Bloxham DP. Specific labelling of a constituent polypeptide of bovine heart mitochondrial reduced nicotinamide adenine dinucleotide ubiquinone reducatase by the inhibitor diphenyleneiodonium. Biochem J 1977;163(3):605-15
   PubMedGoogle Scholar
• Cross AR, Jones OTG. The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labelling of a component polypeptide of the oxidase. Biochem J 1986;237(1):111-16
   PubMedGoogle Scholar
• Ferreira Mendes A, Pato Carvalho A, Margarida Caramona M, Celeste Lopes M. Diphenyleneiodonium inhibits NF-kappaB activation and iNOS expression induced by IL-1beta: involvement of reactive oxygen species. Mediators Inflamm 2001;10(4):209-15
   PubMedGoogle Scholar
• Riganti C, Gazzano E, Polimeni M, et al. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 2004;279(46):47726-31
   PubMedGoogle Scholar
• Hart BA, Simons JM, Rijkers GT, et al. Reaction products of 1-naphthol with reactive oxygen species prevent NADPH oxidase activation in activated human neutrophils, but leave phagocytosis intact. Free Radic Biol Med 1990;8(3):241-9
   PubMedGoogle Scholar
• Hart BA, Elferink JGR, Nibbering PH. Effect of apocynin on the induction of ulcerative lesions in rat skin injected with tubercle bacteria. Int J Immunopharmacol 1992;14(6):953-61
   PubMedGoogle Scholar
• Moe KT, Aulia S, Jiang F, et al. Tumor necrosis factor-alpha in human aortic smooth muscle and embryonic kidney cells. J Cell Mol Med 2006;10(1):231-9
   PubMed Web of Science ®Google Scholar
• Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Superoxide auto-augments superoxide formation and upregulates gp91(phox) expression in porcine pulmonary artery endothelial cells: inhibition by iloprost. Eur J Pharmacol 2006;538(1-3):108-14
   PubMedGoogle Scholar
• Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free radic Biol Med 2007;43(2):271-81
   PubMed Web of Science ®Google Scholar
• Touyz RM. Apocynin, NADPH oxidase, and vascular cells: a complex matter. Hypertension 2008;51(2):172-4
   PubMed Web of Science ®Google Scholar
• Vejrazka M, Mícek R, Stípek S. Apocynin inhibits NADPH oxidase in phagocytes but stimulates ROS production in non-phagocytic cells. Biochim Biophys Acta 2005;1722(2):143-7
   PubMed Web of Science ®Google Scholar
• ten Freyhaus H, Huntgeburth M, Wingler K, et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006;71(2):331-41
   PubMed Web of Science ®Google Scholar
• Wind S, Beuerlein K, Armitage ME, et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 2010;56(3):490-7
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010;8:9
   PubMed Web of Science ®Google Scholar
• Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 2009;459(7249):996-9
   PubMed Web of Science ®Google Scholar
• Page P, Orchard M, Fioraso-Cartier L, Mottironi B. Pyrazolo pyridine derivatives as NADPH oxidase inhibitors, patent WO2008/ 113856 A1. Genkyotex Sa; Switzerland: 2008
   Google Scholar
• Aoyama T, Paik YH, Watanabe S, et al. Nicotinamide adenine dinucleotide phosphate oxidase (nox) in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012;56(6):2316-27
   PubMed Web of Science ®Google Scholar
• Jiang JX, Chen X, Serizawa N, et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012;53(2):289-96
   PubMedGoogle Scholar
• Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53(21):7715-30
   PubMed Web of Science ®Google Scholar
• Vendrov AE, Madamanchi NR, Niu XL, et al. NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis. J Biol Chem 2010;285(34):26545-57
   PubMed Web of Science ®Google Scholar
• Sedeek M, Gutsol A, Montezano AC, et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci 2013;124(3):191-202
   PubMed Web of Science ®Google Scholar
• Di Marco E, Gray SP, Chew P, et al. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe mice. Diabetologia 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Streeter J, Thiel W, Brieger K, Miller FJ Jr. Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. Cardiovasc Ther 2013;31(3):125-37
   PubMed Web of Science ®Google Scholar